Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR0.55), EUR0.40 worse than the analyst estimate of (EUR0.15). Revenue for the quarter came in at EUR240 million versus the consensus estimate of EUR245.68 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.